MarketPeel
Insider Trading Intelligence
Pricing
…
PG

Peter Greenleaf

AUPH
CHIEF EXECUTIVE OFFICER · AURINIA PHARMACEUTICALS INC. · CIK 0001363683
FILING MIX · LIFETIME59%/41%
BUYS
16
SELLS
11
TOTAL VALUE
$9.03M
COMPANIES
2
ACTIVE SINCE
May 2021
HOLDINGS NOW
1,865,437
AVG SELL PX
$10.23
TRADE KIND
SHOWING 27 / 27
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
10 backtested trades · 8 horizons · 8 pendingHow are these numbers computed? →
Forward-return performance of every backtestable P/S trade by Peter Greenleaf, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d10+40.00%+6.51%-0.57%+7.08%+7.01%—
14d10+40.00%+7.17%+1.14%+6.03%+6.62%—
30d10+40.00%+11.79%+2.70%+9.09%+10.47%—
60d10+40.00%+12.58%+1.65%+6.64%+6.02%—
90d10+60.00%+15.53%+5.63%+9.90%+0.20%—
180d10(2 pending)+37.50%+55.88%+10.00%+45.87%+24.13%—
1y10(2 pending)+37.50%+11.09%+12.00%-0.92%-10.76%—
2y10(4 pending)+50.00%+13.76%+27.84%-14.08%-34.70%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
AUPH · 1,840,379 shares · as of Mar 2, 2026
0537,3711,074,7431,612,1142,149,48520222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 16 buys / 11 sellsCOVERAGE · 21 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
PTHS
PELTHOS THERAPEUTICS INC.
SALE10b5-1
10b5-1 plan
377$21.36$8.1K24,681Apr 2, 2026Apr 6, 2026 ↗View →
PTHS
PELTHOS THERAPEUTICS INC.
SALE10b5-1
10b5-1 plan
420$20.52$8.6K25,058Apr 2, 2026Apr 6, 2026 ↗View →
AUPH
AURINIA PHARMACEUTICALS INC.
SALE
Chief Executive Officer
100,890$14.21$1.43M1,840,379Mar 2, 2026Mar 3, 2026 ↗View →
AUPH
AURINIA PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
328,424——328,424Feb 27, 2026Mar 3, 2026 ↗View →
AUPH
AURINIA PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
196,403——1,941,269Feb 27, 2026Mar 3, 2026 ↗View →
AUPH
AURINIA PHARMACEUTICALS INC.
SALE
Chief Executive Officer
100,171$14.40$1.44M1,744,866Feb 20, 2026Feb 23, 2026 ↗View →
AUPH
AURINIA PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
165,384——1,954,329Jan 2, 2026Jan 5, 2026 ↗View →
AUPH
AURINIA PHARMACEUTICALS INC.
SALE
Chief Executive Officer
113,169$15.95$1.81M1,845,037Jan 2, 2026Jan 5, 2026 ↗View →
PTHS
PELTHOS THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
25,478——25,478Jul 2, 2025Jul 7, 2025 ↗View →
PTHS
PELTHOS THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
77,640——77,640Jul 2, 2025Jul 7, 2025 ↗View →
PTHS
PELTHOS THERAPEUTICS INC.
PURCHASEGRANT
Stock grant
25,478——25,478Jul 2, 2025Apr 1, 2026 ↗View →
AUPH
AURINIA PHARMACEUTICALS INC.
SALE
Chief Executive Officer
164,947$7.92$1.31M1,788,945Mar 4, 2025Mar 4, 2025 ↗View →
AUPH
AURINIA PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
333,705——2,149,485Mar 3, 2025Mar 4, 2025 ↗View →
AUPH
AURINIA PHARMACEUTICALS INC.
SALE
Chief Executive Officer
195,593$8.00$1.56M1,953,892Mar 3, 2025Mar 4, 2025 ↗View →
AUPH
AURINIA PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
290,728——1,815,780Feb 28, 2025Mar 4, 2025 ↗View →
AUPH
AURINIA PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
443,973——443,973Feb 28, 2025Mar 4, 2025 ↗View →
AUPH
AURINIA PHARMACEUTICALS INC.
SALE
Chief Executive Officer
126,981$5.60$711.1K1,522,114Mar 6, 2024Mar 7, 2024 ↗View →
AUPH
AURINIA PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
661,538——1,649,095Feb 20, 2024Feb 22, 2024 ↗View →
AUPH
AURINIA PHARMACEUTICALS INC.
SALE
Chief Executive Officer
33,047$8.78$290.2K982,671Mar 2, 2023Feb 22, 2024 ↗View →
AUPH
AURINIA PHARMACEUTICALS INC.
SALE
Chief Executive Officer
32,750$8.94$292.8K982,968Mar 2, 2023Mar 6, 2023 ↗View →
AUPH
AURINIA PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
667,407——1,015,718Mar 2, 2023Mar 6, 2023 ↗View →
AUPH
AURINIA PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
312,240——312,240Mar 2, 2022Mar 4, 2022 ↗View →
AUPH
AURINIA PHARMACEUTICALS INC.
SALE
Chief Executive Officer
9,068$12.01$108.9K32,967Mar 2, 2022Mar 4, 2022 ↗View →
AUPH
AURINIA PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
534,188——534,188Mar 2, 2022Mar 4, 2022 ↗View →
AUPH
AURINIA PHARMACEUTICALS INC.
PURCHASEGRANT
Stock grant
28,300——42,035Mar 2, 2022Mar 4, 2022 ↗View →
AUPH
AURINIA PHARMACEUTICALS INC.
PURCHASE
Chief Executive Officer
2,133$10.15$21.6K10,461May 11, 2021May 12, 2021 ↗View →
AUPH
AURINIA PHARMACEUTICALS INC.
PURCHASE
Chief Executive Officer
2,992$11.11$33.2K13,453May 11, 2021May 12, 2021 ↗View →
Other insiders · AUPH
Loading peer insiders…
About this filer
CIK 0001363683
ROLE
Chief Executive Officer
PRIMARY
AUPH
COMPANIES
2
ACTIVE SINCE
May 2021
MARKETPEEL · /INSIDER/0001363683DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback